Vaneltix Pharma, Inc. is a private clinical stage biotech focused on developing pharmaceutical products for the treatment of urologic conditions with high unmet need, with a focus on bladder conditions that primarily affect women. With 2 significant products in late phase 2 clinical development in bladder pain and incontinence, Alenura(TM) and VNX005, the company is poised to be a leader in these therapeutic areas of Urology and Women's Health Care. Vaneltix also has a full preclinical pipeline and is led by an experienced team of pharmaceutical professionals and renowned Urologists. Our management, and advisors rank among the top experts in bladder dysfunction and urological pain and have significant experience in the FDA approval process for new medicines, preclinical and clinical development, creation of new dosage forms and marketing of Urology & WHC products. The company is poised for success with a number of significant news events over the short term and a potential 2026 exit.